 - Characterization of preference and erectile function among patients who choose to stay on or if on placebo, to start tadalafil, a phosphodiesterase type 5 PDE5 inhibitor other than tadalafil, a non-PDE5-inhibitor erectile aide, or no PDE5 inhibitor or erectile aide at 28-30 weeks and at 1 and 2 years. 